Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy (NCT04741074) | Clinical Trial Compass
TerminatedPhase 3
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
Stopped: low recruitment
United States15 participantsStarted 2021-07-23
Plain-language summary
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients' eligibility for kidney transplantation at the end of 9 months.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. \- Age ≥ 18 years
✓. \- BMI 25-45 kg/m2
✓. \- T2DM
✓. \- Advanced CKD\* (last eGFR \<30 ml/min/1.73m2 in EHR or ESKD on dialysis prior to screening) or stage G3B/A2-3 CKD (eGFR 30 to \<45 ml/min/1.73m2 with albumin/creatinine ratio \>30 mg/g).
Exclusion criteria
✕. \- Ability to provide informed consent before any trial-related activities